Medicxi is a life sciences-focused investment firm, originally created at Index Ventures, a leading international venture capital firm with offices in London, San Francisco, Geneva, and St. Helier (Jersey).

Francesco De Rubertis joined Index at the end of 1997 to launch the firm's life sciences practice and was joined in the following years by three partners: Kevin Johnson, Michèle Ollier and David Grainger. Over the years, Index raised a total of twelve funds, managed with separate life sciences and technology investment teams.

In 2012, Index launched sector-specific venture funds for the first time, raising separately Index Ventures VI (technology focus) and Index Life VI (life sciences focus). Global Pharma GlaxoSmithKline (NYSE: GSK) and affiliates of Johnson & Johnson (Janssen; NYSE: JNJ) both partnered with Index by investing in Index Life VI. This was a key step in the path towards the founding of Medicxi as an independent venture firm. (read here)

Medicxi started its operations in February 2016, with offices in London, Geneva and St Helier (Jersey). Giuseppe Zocco, co-founder of Index Ventures, joined Medicxi shortly thereafter to help build the firm’s late-stage platform and lead the launch of its first Medicxi Growth fund, MG1. (read here)

Currently, the firm is actively investing its 2 most recent funds, Medicxi Ventures 1 (focus on early-stage companies) and Medicxi Growth 1 (focus on later stage companies), in addition to managing the entire portfolio of all prior Index life sciences investments.

The firm is led by its five co-founders and Partners: Francesco, Kevin, Michèle, David and Giuseppe. Over the years, the five of them have collectively been involved in starting over seventy companies in several countries.